WHO strongly recommends antiviral drug for patients with non-severe COVID-19
Dual delivery of BMP2 and IGF1 promotes cranial bone defect healing
21 April 2022Longer interval between COVID-19 vaccines generates up to nine times as many antibodies
22 April 2022WHO strongly recommends antiviral drug for patients with non-severe COVID-19
Pfizer’s oral antiviral drug (a combination of nirmatrelvir and ritonavir tablets) is strongly recommended for patients with non-severe COVID-19 who are at highest risk of hospitalization, such as unvaccinated, older, or immunosuppressed patients, with lack of vaccination as an additional risk factor to consider, says a WHO Guideline Development Group of international experts in The BMJ today.
